Harnessing the power of the endocannabinoid system.

At OCT, we are developing safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions.


Find out more

Therapeutic Areas

OCT is focused on drug development for indications in oncology, pain, immunology and neurology.


Find out more

Our Approach

OCT utilises a range of compounds in drug development, including proprietary cannabinoid derivatives, unmodified phytocannabinoids and terpenes, and in-licensed compounds that target the endocannabinoid system. By utilising a range of inputs, OCT is creating a drug development portfolio that maximises the therapeutic potential of cannabinoids, balances long-term market value, and ensures intellectual property protection across all activities.

Find out more

Recent news, reports & resources


All News

  • Why the Government should continue to invest in Life Sciences post COVID-19

    Why the government should continue to invest in Life Sciences post COVID-19

    01 June 2020 OCT blog - John Lucas, COO
  • OCT researchers publish new study examining genes involved in treating neuropathic pain

    19 April 2020 OCT Press Release
  • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

    03 April 2020 OCT Press Release

Get in touch

Oxford Cannabinoid Technologies Ltd
1 Maddox Street
London W1S 2PZ

Find us on a map